accuray research

Global Tuberculosis (TB) Drugs/Therapeutics Market Analysis & Trends - Industry Forecast to 2027

Share
  • Description
  • Table of Content
  • List of Tables
  • Request Sample

The Global Tuberculosis (TB) Drugs/Therapeutics Market is poised to grow strong during the forecast period 2017 to 2027. Some of the prominent trends that the market is witnessing include increased focus on TB vaccine development and rising the emergence of drug-resistant TB.

Based on Type, the market is categorized into Latent Tuberculosis, Active Tuberculosis and Drug-resistant Tuberculosis. 
 
Depending on Drug Class the market is segregated into First-Line Anti-TB Drugs, Second-Line Anti-TB Drugs and Combination Drugs. In addition, First-Line Anti-TB Drugs is further segmented into Isoniazid, Ethambutol, Pyrazinamide, Rifampicin, Rifabutin, Streptomycin and Other First-Line Anti-TB Drugs. Second-Line Anti-TB Drugs is divided into Cycloserine, Moxifloxacin, Gatifloxacin, Amikacin/Kanamycin, Ethionamide, Capreomycin and Other Second-Line Anti-TB Drugs.
On the basis of Product, the market is bifurcated into Hydrazine derivatives, Isoniazid, Miscellaneous anti tubercular Drugs, Rifampin, Ethambutol and Pyrazinamide.

Based on End User, the market is categorized into Hospital Pharmacies, Ambulatory Surgical Centers and Individual Pharmacies.

This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

 

The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc. The market data is gathered from extensive primary interviews and secondary research. The market size is calculated based on the revenue generated through sales from all the given segments and sub segments in the research scope. The market sizing analysis includes both top-down and bottom-up approaches for data validation and accuracy measures.

 

This report provides data tables, includes charts and graphs for visual analysis.

 

Regional Analysis:

North America

- US

- Canada

- Mexico

 

Europe

- France

- Germany

- Italy

- Spain

- UK

- Rest of Europe

 

Asia Pacific

- China

- Japan

- India

- Australia

- New Zealand

- Rest of Asia Pacific

 

Middle East

- Saudi Arabia 

- UAE  

- Rest of Middle East

 

Latin America

- Argentina 

- Brazil  

- Rest of Latin America

 

Rest of the World

- South Africa

- Others

 

Report Highlights:

- The report provides a detailed analysis on current and future market trends to identify the investment opportunities

- Market forecasts till 2027, using estimated market values as the base numbers

- Key market trends across the business segments, Regions and Countries

- Key developments and strategies observed in the market

- Market Dynamics such as Drivers, Restraints, Opportunities and other trends

- In-depth company profiles of key players and upcoming prominent players

- Growth prospects among the emerging nations through 2027

- Market opportunities and recommendations for new investments


1 Market Outline    
 1.1 Research Methodology  
  1.1.1 Research Approach & Sources 
 1.2 Market Trends   
 1.3 Regulatory Factors   
 1.4 Product Analysis   
 1.5 End User Analysis   
 1.6 Strategic Benchmarking  
 1.7 Opportunity Analysis  
      
2 Executive Summary    
      
3 Market Overview    
 3.1 Current Trends   
  3.1.1 Increased focus on TB vaccine development
  3.1.2 Rising the Emergence of Drug-Resistant TB
  3.1.3 Recent Technological Developments in Tuberculosis (TB) Drugs/Therapeutics
  3.1.4 Growth Opportunities/Investment Opportunities
 3.2 Drivers    
 3.3 Constraints   
 3.4 Industry Attractiveness  
  3.4.1 Bargaining power of suppliers 
  3.4.2 Bargaining power of buyers 
  3.4.3 Threat of substitutes 
  3.4.4 Threat of new entrants 
  3.4.5 Competitive rivalry  
      
4 Tuberculosis (TB) Drugs/Therapeutics Market, By Disease Type
 4.1 Latent Tuberculosis   
  4.1.1  Latent Tuberculosis Market Forecast to 2027 (US$ MN)
 4.2 Active Tuberculosis   
  4.2.1 Active Tuberculosis Market Forecast to 2027 (US$ MN)
 4.3 Drug-resistant Tuberculosis  
  4.3.1 Drug-resistant Tuberculosis Market Forecast to 2027 (US$ MN)
      
5 Tuberculosis (TB) Drugs/Therapeutics Market, By Drug Class
 5.1 First-Line Anti-TB Drugs  
  5.1.1 First-Line Anti-TB Drugs Market Forecast to 2027 (US$ MN)
   5.1.1.1 Isoniazid  
    5.1.1.1.1 Isoniazid Market Forecast to 2027 (US$ MN)
   5.1.1.2 Ethambutol 
    5.1.1.2.1 Ethambutol Market Forecast to 2027 (US$ MN)
   5.1.1.3 Pyrazinamide 
    5.1.1.3.1 Pyrazinamide Market Forecast to 2027 (US$ MN)
   5.1.1.4 Rifampicin 
    5.1.1.4.1 Rifampicin Market Forecast to 2027 (US$ MN)
   5.1.1.5 Rifabutin  
    5.1.1.5.1 Rifabutin Market Forecast to 2027 (US$ MN)
   5.1.1.6 Streptomycin 
    5.1.1.6.1 Streptomycin Market Forecast to 2027 (US$ MN)
   5.1.1.7 Other First-Line Anti-TB Drugs
    5.1.1.7.1 Other First-Line Anti-TB Drugs Market Forecast to 2027 (US$ MN)
 5.2 Second-Line Anti-TB Drugs  
  5.2.1 Second-Line Anti-TB Drugs Market Forecast to 2027 (US$ MN)
   5.2.1.1 Cycloserine 
    5.2.1.1.1 Cycloserine Market Forecast to 2027 (US$ MN)
   5.2.1.2 Moxifloxacin 
    5.2.1.2.1 Moxifloxacin Market Forecast to 2027 (US$ MN)
   5.2.1.3 Gatifloxacin 
    5.2.1.3.1 Gatifloxacin Market Forecast to 2027 (US$ MN)
   5.2.1.4 Amikacin/Kanamycin
    5.2.1.4.1 Amikacin/Kanamycin Market Forecast to 2027 (US$ MN)
   5.2.1.5 Ethionamide 
    5.2.1.5.1 Ethionamide Market Forecast to 2027 (US$ MN)
   5.2.1.6 Capreomycin 
    5.2.1.6.1 Capreomycin Market Forecast to 2027 (US$ MN)
   5.2.1.7 Other Second-Line Anti-TB Drugs
    5.2.1.7.1 Other Second-Line Anti-TB Drugs Market Forecast to 2027 (US$ MN)
 5..3 Combination drugs   
  5.3.1 Combination drugs Market Forecast to 2027 (US$ MN)
      
6 Tuberculosis (TB) Drugs/Therapeutics Market, By Product
 6.1 Hydrazine derivatives  
  6.1.1 Hydrazine derivatives Market Forecast to 2027 (US$ MN)
 6.2 Isoniazid    
  6.2.1 Isoniazid Market Forecast to 2027 (US$ MN)
 6.3 Miscellaneous anti tubercular drugs 
  6.3.1 Miscellaneous anti tubercular drugs Market Forecast to 2027 (US$ MN)
 6.4 Rifampin    
  6.4.1 Rifampin Market Forecast to 2027 (US$ MN)
 6.5 Ethambutol   
  6.5.1 Ethambutol Market Forecast to 2027 (US$ MN)
 6.6 Pyrazinamide   
  6.6.1 Pyrazinamide Market Forecast to 2027 (US$ MN)
      
7 Tuberculosis (TB) Drugs/Therapeutics Market, By End User
 7.1 Hospital Pharmacies  
  7.1.1 Hospital Pharmacies Market Forecast to 2027 (US$ MN)
 7.2 Ambulatory Surgical Centers  
  7.2.1 Ambulatory Surgical Centers Market Forecast to 2027 (US$ MN)
 7.3 Individual Pharmacies  
  7.3.1 Individual Pharmacies Market Forecast to 2027 (US$ MN)
      
8 Tuberculosis (TB) Drugs/Therapeutics Market, By Geography 
 8.1 North America   
  8.1.1 North America Market Forecast by Countries to 2027 (US$ MN)
   8.1.1.1 US  
   8.1.1.2 Canada  
   8.1.1.3 Mexico  
 8.2 Europe    
  8.2.1 Europe Market Forecast by Countries to 2027 (US$ MN)
   8.2.1.1 Germany  
   8.2.1.2 UK  
   8.2.1.3 Italy  
   8.2.1.4 France  
   8.2.1.5 Spain  
   8.2.1.6 Rest of Europe 
 8.3 Asia Pacific   
  8.3.1 Asia Pacific Market Forecast by Countries to 2027 (US$ MN)
   8.3.1.1 China  
   8.3.1.2 Japan  
   8.3.1.3 India  
   8.3.1.4 Australia  
   8.3.1.5 New Zealand 
   8.3.1.6 Rest of Asia Pacific 
 8.4 Middle East   
  8.4.1 Middle East Market Forecast by Countries to 2027 (US$ MN)
   8.4.1.1 Saudi Arabia 
   8.4.1.2 UAE  
   8.4.1.3 Rest of Middle East  
 8.5 Latin America   
  8.5.1 Latin America Market Forecast by Countries to 2027 (US$ MN)
   8.5.1.1 Argentina 
   8.5.1.2 Brazil  
   8.5.1.3 Rest of Latin America 
 8.6 Rest of the World (RoW)  
  8.6.1 RoW Market Forecast by Countries to 2027 (US$ MN) 
   8.6.1.1 South Africa 
   8.6.1.2 Others  
      
9 Key Player Activities   
 9.1 Mergers & Acquisitions  
 9.2 Partnerships, Joint Venture‚Äôs, Collaborations and Agreements
 9.3 Product Launch & Expansions  
 9.4 Other Activities   
      
10 Leading Companies     
 10.1 Novartis AG   
 10.2 AstraZeneca PLC   
 10.3 Pfizer Inc.   
 10.4 Bayer AG    
 10.5 Sandoz International GmbH  
 10.6 Eli Lilly and Company  
 10.7 Sanofi    
 10.8 GlaxoSmithKline plc  
 10.9 Macleods Pharmaceuticals Limited 
 10.10 Johnson & Johnson   
 10.11 Otsuka Pharmaceutical Co., Ltd 
 10.12 Lupin Pharmaceuticals Inc  
      

Table 1 Global Tuberculosos (TB) Drugs/Therapeutics Market By Region, Market Forecast (2015-2027) (US$ MN)
Table 2 Global Tuberculosos (TB) Drugs/Therapeutics Market By Disease Type, Market Forecast (2015-2027) (US$ MN)
Table 3 Global Tuberculosos (TB) Drugs/Therapeutics Market By Latent Tuberculosis, Market Forecast (2015-2027) (US$ MN)
Table 4 Global Tuberculosos (TB) Drugs/Therapeutics Market By Active Tuberculosis, Market Forecast (2015-2027) (US$ MN)
Table 5 Global Tuberculosos (TB) Drugs/Therapeutics Market By Drug-resistant Tuberculosis, Market Forecast (2015-2027) (US$ MN)
Table 6 Global Tuberculosos (TB) Drugs/Therapeutics Market By Drug Class, Market Forecast (2015-2027) (US$ MN)
Table 7 Global Tuberculosos (TB) Drugs/Therapeutics Market By First-Line Anti-TB Drugs, Market Forecast (2015-2027) (US$ MN)
Table 8 Global Tuberculosos (TB) Drugs/Therapeutics Market By Isoniazid, Market Forecast (2015-2027) (US$ MN)
Table 9 Global Tuberculosos (TB) Drugs/Therapeutics Market By Ethambutol, Market Forecast (2015-2027) (US$ MN)
Table 10 Global Tuberculosos (TB) Drugs/Therapeutics Market By Pyrazinamide, Market Forecast (2015-2027) (US$ MN)
Table 11 Global Tuberculosos (TB) Drugs/Therapeutics Market By Rifampicin, Market Forecast (2015-2027) (US$ MN)
Table 12 Global Tuberculosos (TB) Drugs/Therapeutics Market By Rifabutin, Market Forecast (2015-2027) (US$ MN)
Table 13 Global Tuberculosos (TB) Drugs/Therapeutics Market By Streptomycin, Market Forecast (2015-2027) (US$ MN)
Table 14 Global Tuberculosos (TB) Drugs/Therapeutics Market By Other First-Line Anti-TB Drugs, Market Forecast (2015-2027) (US$ MN)
Table 15 Global Tuberculosos (TB) Drugs/Therapeutics Market By Second-line anti-TB drugs, Market Forecast (2015-2027) (US$ MN)
Table 16 Global Tuberculosos (TB) Drugs/Therapeutics Market By Cycloserine, Market Forecast (2015-2027) (US$ MN)
Table 17 Global Tuberculosos (TB) Drugs/Therapeutics Market By Moxifloxacin, Market Forecast (2015-2027) (US$ MN)
Table 18 Global Tuberculosos (TB) Drugs/Therapeutics Market By Gatifloxacin, Market Forecast (2015-2027) (US$ MN)
Table 19 Global Tuberculosos (TB) Drugs/Therapeutics Market By Amikacin/Kanamycin, Market Forecast (2015-2027) (US$ MN)
Table 20 Global Tuberculosos (TB) Drugs/Therapeutics Market By Ethionamide, Market Forecast (2015-2027) (US$ MN)
Table 21 Global Tuberculosos (TB) Drugs/Therapeutics Market By Capreomycin, Market Forecast (2015-2027) (US$ MN)
Table 22 Global Tuberculosos (TB) Drugs/Therapeutics Market By Other Second-line anti-TB drugs, Market Forecast (2015-2027) (US$ MN)
Table 23 Global Tuberculosos (TB) Drugs/Therapeutics Market By Combination drugs, Market Forecast (2015-2027) (US$ MN)
Table 24 Global Tuberculosos (TB) Drugs/Therapeutics Market By Product, Market Forecast (2015-2027) (US$ MN)
Table 25 Global Tuberculosos (TB) Drugs/Therapeutics Market By Hydrazine derivatives, Market Forecast (2015-2027) (US$ MN)
Table 26 Global Tuberculosos (TB) Drugs/Therapeutics Market By Isoniazid, Market Forecast (2015-2027) (US$ MN)
Table 27 Global Tuberculosos (TB) Drugs/Therapeutics Market By Miscellaneous anti tubercular drugs, Market Forecast (2015-2027) (US$ MN)
Table 28 Global Tuberculosos (TB) Drugs/Therapeutics Market By Rifampin, Market Forecast (2015-2027) (US$ MN)
Table 29 Global Tuberculosos (TB) Drugs/Therapeutics Market By Ethambutol, Market Forecast (2015-2027) (US$ MN)
Table 30 Global Tuberculosos (TB) Drugs/Therapeutics Market By Pyrazinamide, Market Forecast (2015-2027) (US$ MN)
Table 31 Global Tuberculosos (TB) Drugs/Therapeutics Market By End User, Market Forecast (2015-2027) (US$ MN)
Table 32 Global Tuberculosos (TB) Drugs/Therapeutics Market By Hospital Pharmacies, Market Forecast (2015-2027) (US$ MN)
Table 33 Global Tuberculosos (TB) Drugs/Therapeutics Market By Ambulatory Surgical Centers, Market Forecast (2015-2027) (US$ MN)
Table 34 Global Tuberculosos (TB) Drugs/Therapeutics Market By Individual Pharmacies, Market Forecast (2015-2027) (US$ MN)
 Note: Tables for North America, Europe, APAC, Middle East, Latin America and RoW Regions are also represented in the same manner as above

Speak to Analyst

Request for Discount

Need a Customized Report

Request Sample

clicking on ".ar__close" removes class "open" on ".ar__modal" clicking on ".search_btn" toggles class "open" on "#search_md" clicking on "#category_dd_btn" toggles class "open" on "#category_dd" clicking on ".dp__backdrop" removes class "open" on "#category_dd" clicking on "#category_dd__md_btn" toggles class "open" on "#category_dd_mb" clicking on ".dp__backdrop" removes class "open" on "#category_dd_mb" clicking on ".nav__dp" toggles class "hidden" on "#nav_menu" clicking on ".dp__md_backdrop" removes class "open" on ".ar__modal" clicking on ".analyst_btn" adds class "open" on "#analyst_md" clicking on ".discount_btn" adds class "open" on "#discount_md" clicking on ".customization_btn" adds class "open" on "#customization_md" clicking on ".sample_btn" adds class "open" on "#sample_md" clicking on ".tab-btn" removes class "active" on ".tab-btn.active" clicking on ".tab-btn" removes class "active" on ".tab-context.active" clicking on ".tab-btn" adds class "active" on "target" clicking on "#tab1" adds class "active" on "#tab-wn1" clicking on "#tab2" adds class "active" on "#tab-wn2" clicking on "#tab3" adds class "active" on "#tab-wn3"